MAP2 and Alzheimer disease: Furthermore, SUL-138 treatment of APP/PS1 mice induced an opposite direction of regulation of the AD-associated proteins APP, CLU, IDE, MAP2, LMNB1, LMNA, and GFAP (Figure S6B) compared to the APP VEH vs. WT VEH contrast (Figure S6A), indicating that SUL-138 treatment partially precludes AD-associated protein expression.